$CC

Dignam Denise purchased $51K of CC

Dignam Denise (Chief Executive Officer) purchased 3,378 shares of Chemours Co (CC) at $14.95 on 2026-08-11.

Original reporting
SEC EDGAR · Dignam Denise
Published Aug 13, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Bullish
medium confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCBullishLow
01

Why it matters

This is a primary-source insider buy, which can modestly support sentiment, but it does not introduce new guidance, earnings, contracts, or regulatory developments.

02

Market read

Traders may note the CEO buying as a small bullish signal, but the lack of fundamental updates limits tradable impact.

03

What to watch

The article states no 10b5-1 plan and provides trade price and share count, but it does not indicate whether this is part of a broader pattern of buys/sells or whether other insiders are acting similarly.

Relevance 4/10Novelty 5/10Timing: Form 4 filed Aug 13, covering an Aug 11 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours (CC), reporting an open-market purchase by the CEO.

Company-level read

Ticker impact

$CCBullishMedium confidence
Context

Chemours CEO Dignam Denise bought 3,378 shares in an open-market transaction at $14.95/share, disclosed via Form 4 filed Aug 13.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no new company fundamentals, and the trade size is not large enough to imply a major re-rating by itself.

Market effects

Minimal; insider buying in one chemical company rarely changes sector expectations without accompanying operational or guidance news.

Minimal; Chemours is US-listed and the disclosure is company-specific.

Minimal; no cross-border deal, regulation, or macro linkage is described.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-planned liquidity needs) and do not necessarily reflect a change in near-term fundamentals.

Key entities

  • Chemours Co

    US-listed company whose CEO insider purchase is disclosed on Form 4.

  • Dignam Denise

    Chief Executive Officer and reporting person who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCMedAI 8/10

Environmental groups allege Chemours hasn't met PFAS limits agreement

Cape Fear River Watch alleges Chemours has failed to meet pollution limits agreed upon in a 2019 consent order, claiming the company's groundwater and air emissions controls are inadequate. Chemours disputes these claims, stating it has spent $1.2 billion complying with the order. The environmental group filed a formal notice, citing high levels of PFAS in surface water and groundwater around the plant.

$CCMed

Chemours (CC) Shares Jumped, What Is Behind The Latest Move?

Chemours (CC) shares rose 3.10% after agreeing to a settlement with North Carolina and nearby communities over emissions. The stock is at $14.98, down 29.24% over 90 days. Analysts view it as undervalued at a fair value of $19.78, citing growth in advanced materials and cost optimization. However, PFAS liabilities and regulations pose risks.

$CCMedAI 8/10

What Chemours (CC)'s PFAS Settlement Means For Shareholders

Chemours (CC), DuPont, and Corteva agreed to a US$455 million settlement over PFAS emissions, shared equally. Payments will span 15 years, adjusting cost accounting under a US$4 billion cap. Chemours aims to recover profits by 2029, with revenue and earnings projections of US$6.6 billion and US$686.0 million, respectively, despite current losses. Analysts highlight operational execution and PFAS liability management as key factors.

$CCMedAI 8/10

North Carolina, Chemical Companies Reach $455M PFAS Contamination Settlement

Chemours, DuPont, and Corteva agreed to pay $455M over 15 years to settle PFAS contamination claims in North Carolina. Chemours will cover half, with the rest split between DuPont and Corteva. The funds will support state and local remediation efforts. The companies have already spent or committed significant sums for cleanup and penalties.